Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Scientists at Huazhong University of Science and Technology describe research in vaccines
November 12th, 2008
Research findings, 'The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10,' are discussed in a new report. "The purpose of the present study was to evaluate the anti-vasculature effects and the anti-tumor effects of attenuated Salmonella typhimurium vaccine strain encoding murine vascular endothelial growth factor (VEGF) receptor-2 (flk1) in combination with plasmid DNA vector encoding the murine interferon-induced protein of 10kDa (IP-10 or CXCL10) gene. Mouse models of malignant melanoma (B16-F10) were treated with combining orally given attenuated S. typhimurium vaccine strain encoding flk1 with direct intratumoral injection of a...
Source: Vaccine Weekly (2008-11-12)
|
|
Advertisement |
|
|
|
